Enpro (NPO) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
23 Dec, 2025Executive summary
2024 sales declined 1.0% year-over-year to $1,048.7M, with organic sales down 3.9%, reflecting semiconductor and commercial vehicle market weakness offset by strength in nuclear, aerospace, and food/pharma.
Adjusted EBITDA rose 7.1% to $254.8M, with margin expanding 180 bps to 24.3% due to improved mix, cost initiatives, and lower share-based compensation.
Q4 2024 sales grew 3.7% year-over-year to $258.4M, with gross margin up 360 bps and adjusted diluted EPS up 31.9% to $1.57.
Sealing Technologies segment offset softness in Advanced Surface Technologies, driving improved year-over-year bottom line results.
Launched Enpro 3.0, focusing on higher revenue growth, best-in-class profitability, and strong returns on invested capital.
Financial highlights
Full-year adjusted EBITDA margin reached 24.3%, up from 22.5% in 2023.
Free cash flow for 2024 was $130.0M, down from $174.1M in 2023 due to higher cash taxes.
Adjusted diluted EPS for Q4 was $1.57, up 32% from prior year; full-year adjusted diluted EPS was $6.96, up 6.4%.
Paid $25.3M in dividends in 2024; quarterly dividend increased to $0.31 per share, marking the tenth consecutive annual increase.
Net debt at year-end was $406M, with $236.3M in cash and $390M available under the credit facility.
Outlook and guidance
2025 revenue growth expected in the low to mid-single digits.
2025 adjusted EBITDA guidance: $262M–$277M; adjusted diluted EPS: $7.00–$7.70.
Sealing Technologies: low- to mid-single-digit revenue growth, adjusted segment EBITDA margin to exceed 30%.
Advanced Surface Technologies: mid to high single-digit sales growth, margins above 20%, with stronger second half expected.
2025 capital expenditures expected to be ~$50M (4.5% of sales); assumptions include $101–103M depreciation/amortization and $34–36M net interest.
Latest events from Enpro
- Strong 2025 results and 2026 growth outlook driven by high-margin tech focus and strategic acquisitions.NPO
Investor presentation18 Feb 2026 - Strong 2025 growth and margin expansion set the stage for robust 2026 performance.NPO
Q4 202518 Feb 2026 - Adjusted EBITDA rose 14% to $74.0M as Sealing Technologies offset semiconductor weakness.NPO
Q2 20242 Feb 2026 - Q3 2024 sales and margins rose, but guidance was cut on semiconductor and OEM weakness.NPO
Q3 202416 Jan 2026 - Portfolio transformation and operational excellence drive strong margins and growth outlook.NPO
Sidoti Small-Cap Virtual Investor Conference11 Jan 2026 - Accelerating profitable growth with 30%+ margins and strategic expansion in technology sectors.NPO
Gabelli Funds 35th Annual Pump, Valve & Water Symposium23 Dec 2025 - Proxy covers director elections, executive pay, equity plan, auditor, and ESG priorities.NPO
Proxy Filing1 Dec 2025 - Director Adele M. Gulfo joins NewAmsterdam Pharma's board ahead of her re-election vote.NPO
Proxy Filing1 Dec 2025 - Director Ronald C. Keating joins Hayward Holdings' board; biography updated for 2025 vote.NPO
Proxy Filing1 Dec 2025